Equity Overview
Price & Market Data
Price: $0.69
Daily Change: -$0.021 / 3.04%
Daily Range: $0.626 - $0.74
Market Cap: $41,969,260
Daily Volume: 1,743,030
Performance Metrics
1 Week: 15.57%
1 Month: 27.18%
3 Months: 90.87%
6 Months: 3.74%
1 Year: 3.19%
YTD: -3.46%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country:
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.